Patients with a high probability of HFpEF may experience greater benefits from atrial fibrillation ablation than those with a ...

The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated ...

A new study published in the Journal of the American College of Cardiology showed that the patients with atrial fibrillation ...

Sky Labs, a health-tech startup based in South Korea, announced that its ring-shaped smart medical device, CART-I (Cardio ...

You may be able to lower your risk for developing heart rhythm abnormalities by speeding up your walking pace. That’s according to a large new study published Tuesday in the journal Heart, which found ...

Catheter Ablation Devices for Atrial Fibrillation Market 2035, Driven by advanced devices, better clinical outcomes, and rising regulatory approvals.

A lower apixaban dose is indicated in patients with an eGFR less than 30 mL/min/1.73 m2, regardless of dialysis status.

The study was published online in JAMA Neurology on March 31, 2025.

The manufacturer reports that the system delivers reliable results, particularly in the detection of atrial fibrillation ... An example of such a measurement protocol can be viewed on the ...

1 The notion that greater infarct size and stroke severity linearly increase the risk of bleeding associated with anticoagulation remains embedded in clinical guidelines ... patients with ischemic ...

In patients with AF, abelacimab, compared with rivaroxaban, is associated with decreased bleeding across multiple bleeding risk categories. Abelacimab is associated with reduced bleeding compared ...